BackCentury Therapeutics Overview

Century Therapeutics Other Current Liabilities

Century Therapeutics's other current liabilities is $10M.

Get informed when a big investor buys or sells

+ Follow
Other Current Liabilities
$10.42M
41.58% YoYΔ $3.06M vs prior year quarter

Peer average

Loading

Century Therapeutics Other Current Liabilities History

Loading

Century Therapeutics vs. peers: Other Current Liabilities Comparison

Loading

Century Therapeutics Other Current Liabilities Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Century Therapeutics (IPSC) FAQ

As of the most recent data (March 2026), IPSC shows a other current liabilities of $10M. That compares with $7.4M in the prior-year period — up 41.6% year over year. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, IPSC's other current liabilities is now $10M (was $7.4M) — a 41.6% year-over-year increase. Pairing that YoY change with peer averages gives a clearer picture of whether Century Therapeutics is outperforming or lagging.

Tracking IPSC's other current liabilities over time shows whether Century Therapeutics is scaling, shrinking, or reshaping that part of the business. The current reading is $10M That compares with $7.4M in the prior-year period — up 41.6% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this other current liabilities page, Stockcircle has Century Therapeutics's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect other current liabilities (currently $10M) with ownership activity and broader fundamentals.

Century Therapeutics's other current liabilities is $10M; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.